Table 2.
Clinical trials investigating neutrophil-targeting agents in TNBC
| Target | Intervention | Effects on neutrophils | Status | Clinical trial ID |
|---|---|---|---|---|
| COX-2 | Celebrex | Downregulation of Arg1, Nos2 and COX-2 | Completed | NCT00056082 |
| HDACs | Suberoylanilide hydroxamic acid | Inhibiting immunosuppression | Withdrawn | NCT01695057 |
| HDACs | Belinostat | Inhibiting immunosuppression | Recruiting | NCT04315233 |
| HDACs | Vorinostat | Inhibiting immunosuppression | Completed | NCT00574587 |
| HDACs | Entinostat | Inhibiting immunosuppression | Completed | NCT02708680 |
| PTKs | Sorafenib, Apatinib, Famitinib | Induction of apoptosis | Recruiting | NCT05594095 |
| TGFβ | Fresolimumab | Neutralizing TGFβ | Completed | NCT01401062 |
| TGFBR1 | Galunisertib | Inhibiting TGFβ receptor I | Active, not recruiting | NCT02672475 |